| Original article |
|
|
|
|
|
Biflavone Ginkgetin,a Novel Wnt Inhibitor,Suppresses the Growth of Medulloblastoma |
| Zhen-Nan Ye1,2, Mu-Yuan Yu1,2, Ling-Mei Kong1,2, Wei-Hua Wang1,2, Yuan-Feng Yang1,2, Jie-Qing Liu1, Ming-Hua Qiu1, Yan Li1 |
1. State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan, China;
2. University of Chinese Academy of Sciences, Beijing 100049, China |
|
|
|
|
Abstract Medulloblastoma(MB) is a form of malignant brain tumor that predominantly arises in infants and children, of which approximately 25% is due to upregulation of canonical Wnt pathway with mainly mutations in CTNNB1. Therefore, Wnt inhibitors could offer rational therapeutic strategies and chemoprevention for this malignant cancer. In our present study, we undertook a screening for antagonists of Wnt signaling from 600 natural compounds, and identified Ginkgetin, a biflavone isolated from Cephalotaxus fortunei var. alpina. Ginkgetin inhibited Wnt pathway with an IC50 value around 5.92 μM and structure-activity relationship analysis suggested the methoxy group in Ginkgetin as a functional group. Biflavone Ginkgetin showed obvious cytotoxicity in Daoy and D283 MB cells. Cell cycle analysis by flow cytometry showed that Ginkgetin induced efficiently G2/M phase arrest in Daoy cells. Further mechanism studies showed that Ginkgetin reduced the expression of Wnt target genes, including Axin2, cyclinD1 and survivin in MB cells. The phosphorylation level of β-catenin also decreased in a time-and concentration-dependent manner. Collectively, our data suggest that Ginkgetin is a novel inhibitor of Wnt signaling, and as such warrants further exploration as a promising antimedulloblastoma candidate.
|
| Keywords
Wnt signaling
Medulloblastoma
Inhibitor
Biflavone
Ginkgetin
|
| Fund:This work was supported financially by the hundreds top talents program from Chinese Academy of Sciences, the NSFC(Nos. 81173076, 81403050), and the projects of science and technology of Yunnan Province(2009C1120, 2013FA047). |
|
Issue Date: 11 February 2018
|
|
|
1. A.M. Martin, E. Raabe, C. Eberhart, K.J. Cohen, Curr. Treat. Option. Oncol. 15, 581-594 (2014)
2. P. Bailey, H. Cushing, J. Neuropathol. Exp. Neurol. 29, 583-600 (1970)
3. M.E. Kadin, L.J. Rubinstein, J.S. Nelson, J. Neuropathol. Exp. Neurol. 29, 583-600 (1970)
4. S. Marino, Trends Mol. Med. 11, 17-22 (2005)
5. X. Fan, C.G. Eberhart, J. Clin. Oncol. 26, 2821-2827 (2008)
6. D.N. Louis, H. Ohgaki, O.D. Wiestler, Acta Neuropathol. 114, 97-109 (2007)
7. S.R. Hamilton, B. Liu, R.E. Parsons, N. Engl. J. Med. 332, 839-847 (1995)
8. C.G. Eberhart, T. Tihan, P.C. Burger, J. Neuropathol. Exp. Neurol. 59, 333-337 (2000)
9. H. Huang, B.M. Mahler-Araujo, A. Sankila, Am. J. Pathol. 156, 433-437 (2000)
10. N. Baeza, J. Masuoka, P. Kleihues, Oncogene 22, 632-636 (2003)
11. B. Manoranjan, C. Venugopal, N. McFarlane, Cancer Lett. 338, 23-31 (2013)
12. S.C. Clifford, M.E. Lusher, J.C. Lindsey, Cell Cycle 5, 2666-2670 (2006)
13. T. Pietsch, A. Waha, A. Koch, Cancer Res. 57, 2085-2088 (1997)
14. M.D. Taylor, L. Liu, C. Raffel, Nat. Genet. 31, 306-310 (2002)
15. J. Reifenberger, M. Wolter, R.G. Weber, Cancer Res. 58, 1798-1803 (1998)
16. P.A. Northcott, A. Korshunov, H. Witt, J. Clin. Oncol. 29, 1408-1414 (2011)
17. M.D. Taylor, P.A. Northcott, A. Korshunov, Acta Neuropathol. 123, 465-472 (2012)
18. J.R. Crawford, T.J. MacDonald, R.J. Packer, Lancet Neurol. 6, 1073-1085 (2007)
19. C.H. Pui, A.J. Gajjar, J.R. Kane, Nat. Rev. Clin. Oncol. 8, 540-549 (2011)
20. R. Vibhakar, G. Foltz, J.G. Yoon, Neuro-oncology 9, 135-144 (2007)
21. F. Cimmino, M.N. Scoppettuolo, M. Carotenuto, J. Neuro-oncol. 106, 59-70 (2012)
22. N. Baryawno, B. Sveinbjornsson, S. Eksborg, Cancer Res. 70, 266-276 (2010)
23. S. Asuthkar, C.S. Gondi, A.K. Nalla, J. Biol. Chem. 287, 20576-20589 (2012)
24. X.Y. Li, Y.Y. Wang, C.M. Yuan, Nat. Prod. Bioprospect. 3, 24-28 (2013)
25. M. Joly, Phytochemistry 19, 1999-2002 (1980)
26. Y.L. Ren, J.S. Yang, Chin. Pharm. J. 36, 590-593 (2001)
27. H.K. Yao, Chem. Pharm. Bull. 48, 440-441 (2000)
28. W.X. Zhang, W.F. Bao, Acta Pharm. Sin. 35, 124-127 (2000)
29. H.K. Yao, Chem. Pharm. Bull. 50, 1607-1608 (2003)
30. M. Narwal, J. Koivunen, T. Haikarainen, J. Med. Chem. 56, 7880-7889 (2013)
31. A.J. Guo, R.C. Choi, A.W. Cheung, J. Biol. Chem. 286, 27882-27893 (2011)
32. R.H. Zurawel, S.A. Chiappa, C. Allen, Cancer Res. 58, 896-899 (1998)
33. N. Yokota, T.G. Mainprize, M.D. Taylor, Oncogene 23, 3444-3453 (2004)
34. R. Salaroli, A. Russo, C. Ceccarelli, Ultrastruct. Pathol. 31, 33-44 (2007)
35. A. Gregorieff, H. Clevers, Gene. Dev. 19, 877-890 (2005)
36. C. Niehrs, S.P. Acebron, EMBO J. 31, 2705-2713 (2012)
37. M.V. Hadjihannas, M. Bruckner, B. Jerchow, P. Natl, Acad. Sci. USA 103, 10747-10752 (2006)
38. A. Giodini, M.J. Kallio, N.R. Wall, Cancer Res. 62, 2462-2467 (2002)
39. J.Y. Leung, F.T. Kolligs, R. Wu, J. Biol. Chem. 277, 21657-21665 (2002)
40. O. Tetsu, F. McCormick, Nature 398, 422-426 (1999)
41. T. Zhang, T. Otevrel, Z.Q. Gao, Cancer Res. 61, 8664-8667 (2001)
42. H. Clevers, Cell 127, 469-480 (2006)
43. X.Y. Li, J.X. Pu, S. Jiang, PLoS One 8, e68525 (2013) |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
